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ABSTRACT: Much of the excess mortality in diabetic subjects is due to cardiovascular disease, 
Diabetic subjects are at increased risk of developing coronary artery disease and have a higher case 
fatality after acute myocardial infarction and after unstable angina. Diabetes is associated with 
microvascular disease, accelerated atherogenesis and left ventricular dysfunction. We review the 
data on the epidemiology, pathogenesis and management of coronary artery disease in diabetic 
patients. 
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Introduction 
Diabetic patients have a 2-3 fold increased risk of 
cardiovascular mortality. This has been documented in 
the Framingham study 1 and subsequently confirmed by 
other investigators 2.3, The increased atherogenesis in 
diabetic subjects is probably multifactorial; contributory 
factors include increased prevalence of dyslipidaemia 4-6, 
increased platelet adhesiveness and activation 7,8, 
decreased fibrinolysis secondary to increased 
plasminogen activator inhibitor 9.10, hyperfibrino­
genaemia II and abnormal glycation of intimal 
proteins 12.13, In addition to increased atherosclerosis 
leading to macrovascular (large vessel) disease, there is 
also a substantial body of evidence implicating a more 
specific microvascular disease in diabetic subjects 14-17, 
It is thought that initially there is increased 
microvascular pressure and now leading to 
microvascular endothelial injury and basement 
membrane thickening 18. 
A particularly interesting aspect is that of insulin 
resistance in type 2 diabetes. Reaven hypothesised that 
insulin resistance and subsequent compensatory 
hyperinsulinaemia are the basic defects in the so-called 
syndrome X 19, Only when the pancreas fails to secrete 
enough insulin to overcome peripheral resistance does 
clinical diabetes develop. Hyperinsulinaemia and insulin 
resistance are thought to predispose not only to diabetes 
but also to obesity, hypertension, dyslipidaemia ,md 
cardiovascular disease 20,21, There is considerable 
evidence for the clustering of cardiovascular risk factors 
in patients with high fasting insulin levels 22.2:1, Indeed 
there is also evidence that the increased cardiovascular 
risk in type 2 diabetic subjects predates the onset of 
diabetes 24,25; this is consistent with the notion of 
hyperinsulinaemia being an independent risk factor. It 
is, however, not known whether hyperinsulinaemia and 
insulin resistance are the basic defects leading to 
increased risk of coronary artery disease or whether they 
are markers of a genetic predisposition, It should be 
noted that type 1 ,md non-obese type 2 diabetic patients 
are usually insulinopaenic. Hyperinsulinaemia cannot , 
therefore, be the sole mechanism involved. 
Acute myocardial infarction 
Approximately one third of all acute myocardial 
infarctions in Malta occur in diabetic patients. This has 
been documented by Zammit Maempel in 1978 26 and 
more recently by Pullicino et al 27 and by our own 
group 28. This proportion is much higher than that in 
other countries, such as the 16% reported in the 
Minnesota Heart Survey 29 and is consistent with a high 
prevalence of non-insulin dependent diabetes mellitus in 
Malta. 
Not only do diabetic subjects have an increased 
prevalence of coronary artery disease but they also 
exhibit a higher case fatality after acute myocardial 
infarction (AMI). Early studies done before the advent 
of coronary care units showed a mortality of 40-60% in 
diabetic subjects 30.3 1, Later studies showed that, 
although mortality had decreased, it was still higher than 
in non-diabetic patients. For example, in the Minnesota 
Heart Survey 29 the mortaltiy was 18.0% in diabetic 
males and 10.1 % in non-diabetic males (there was no 
statistically significant difference in mortality between 
diabetic and non-diabetic females in this study). 
As these studies were done in the pre-thrombolytic era, 
we investigated the effect of diabetes on mortality in the 
modern era in a prospective case-control study 28. We 
found a three month mortality of 17.3% in diabetic 
patients compared to 10.2% in controls (p<0.05). Our 
data is consistent with that of the GISSI-2 trial 32 and 
International Tissue Plasminogen Activator/ 
Streptokinase Mortality Trial 33, both of which also 
showed a higher mortality 111 diabetic subjects. 
However, both these studies only considered patients 
recelVlng thrombolytic therapy, Those with 
contraindications to thrombolysis, who are more likel y to 
have complications were excluded; this mighl ha ve 
introduced a selection bias, 
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Left ventricular failure 
We found that the prevalence of left ventricular failure 
after AM[ was approximately twice as high in diabetic 
subjects as in controls (38.3% vs 16.8%, p<O.OOI) and 
the prevalence of cardiogenic shock approximately three 
times (9.7% vs 3.6%, p<0.05) 26. This is similar to the 
data from the Minnesota Heart Survey 2') and that 
reported by Yudkin & Oswald 34 . [t should be noted that 
lef't ventricular fail ure 35 -37 and dilation 38 are strong 
predictors of an unfavourable outcome after AMI in the 
general population; this IS possibly related to 
remodelling of the non-infarcted myocardium 3'1 . It is 
therefore probable that the excess mortality observed in 
diabetic patients with AM[ is related to the increased 
prevalence of left ventricular failure; if this is so 
angiotensin converting enzyme inhibition might be 
particularly beneficial in diabetic patients. 
It is interesting that the increased prevalence of heart 
failure in diabetic subjects occurs in spite of a similar 
infarct size 28.34.40. There is evidence for the existence 
of non-ischaemic congestive cardiomyopathy in diabetic 
subjects 41-45; this could be related to non-enzymatic 
glycosy lation of myocardial proteins 45. It is also 
probable that diabetic patients with AMI have more 
extensive coronary artery disease so that parts of the 
non-infarcted myocardium are ischaemic. 
Thrombolytic data 
In our study we found that only 23.5% of diabetic 
subjects compared to 34.2% of controls (p<0.05) 
received thrombolytic therapy 28 and that this difference 
was mainly due to the presence of proliferative 
retinopathy 46. This aroused considerable interest. 
Commenting in a recent leader in the BMJ, Ward & 
Yudkin 47 have suggested that proliferative diabetic 
retinopathy should no longer be regarded as 
contraindication to thrombolysis (as is presently 
generally accepted). They point out that there have been 
only two case reports of ocular haemorrhage occurring 
after thrombolytic therapy: one in a diabetic patient 48 
and the other in a non-diabetic patient 4'1. This has to be 
set against the undoubted benefit of thrombolytic therapy 
in diabetic subjects 50. However, intraocular 
haemorrhage following thrombolytic therapy in diabetic 
patients may be under-reported , especially if physicians 
regard it as a recognised complication. Furthermore, 
intraocular bleeding may be rare only because 
thrombolytic therapy is rarely given to those with 
proliferative diabetic retinopathy . [n a retrospective 
analysis of 507 diabetic patients admitted with acute 
myocardial infarction, we found ' that of the 172 who 
received thrombolytic therapy, only 14 had diabetic 
retinopathy and none had proliferative changes. Of the 
26 with proliferative retinopathy none received 
thrombolytic therapy 51. 
Gray et a[ 52 and our own group 28 have shown that 
thrombolyzed diabetic patients are less likely than non­
diabetic ones to show clinical evidence of reperfusion. 
The latter has been shown to correlate well with 
angiographic data 53. The reasons for the less successful 
thrombolysis are unclear but could include a larger fixed 
stenosis, microvascular disease and resistance to 
thrombolytic agents due to abnormalities 111 the 
coagulation and/or fibrinolytic systems. 
Risk stratification after AMI 
An important aspect in the care of both diabetic and 
non-diabetic patients with AM [ IS that of risk 
stratification, namely the identification of those patients 
at the highest risk of further adverse events. This will 
help in the best utilisation of resources by selecting those 
pati ents most likely to benefit from aggressive 
management whilst at the same time avoiding 
unnecessary investigations in those who are at low risk . 
As stated previously , the presence of clinical, 
radiological or echocardiographic evidence of left 
ventricular failure correlates very strongly with poor 
outcome 34-3g [t is important to de tect these patients as 
they will benefit Crom angiotensin converting enzyllle 
(ACE) inhibition 54-55. 
Our group was the first to show the correlation of loss 
of heart rate variability to mortality after AMI in diabetic 
subjects 28; this has also been confirmed in non-diabetic 
subjects and has been shown to correlate with the risk of 
arrhthymias 56.57. Loss of heart rate variability can be 
detected with Holter monitoring. The latter technique is 
also useful in detecting myocardial ischaemia which is 
another predictor of an adverse outcome 58-59 Holter 
monitoring is especially useful in the risk stratification of 
those who cannot undergo exercise stress testing. 
In a study of 333 diabetic patients admitted with acute 
myocardial infarction, we found that blood glucose on 
admission correlates very strongly with mortality (r = 
0.92, p<0.05) 60_ Interesting[y, most of the excess 
mortality of diabetic patients with AMI occurred in those 
with hyperglycaemia . It is probable that hyperglycaemia 
after AMI is a marker of a stress hormone response but it 
is also possible that hyperglycaemia may itself be toxic 
to the myocardium. Whatever the mechanism, a high 
blood glucose can serve as an inexpensive, minimally 
invasive and readily available predictor of poor outcome 
in diabetic patients with AMI. 
As in non-diabetic patients, exercise stress testing can 
also be used in risk stratification. A positi ve stress test is 
associated with poor outcome 61.62 and selects those 
patients requiring more intensive management. 
Finally post-infarct angina is associated with an up to a 
10-fold increased risk of early re-infarction and 
death 63.64.65. These patients should therefore proceed to 
early angiography and possible revascularisation; there 
is usually little point in doing exercise testing in this 
group. 
Circadian rhythm of AMI 
There is currently great interest in circadian rhythms of 
physiological parameters in relation to occurrence of 
certain diseases. AMI shows a significant morning peak 
in non-diabetic subjects 66-68; this is probably related to 
a · morning increase in platelet adhesiveness 68.69, a 
morning decline in fibrinolytic activity 70.71 and a 
morning rise in arterial blood pressure 72.13 and in blood 
viscosity 74 [nterestingly, we have demonstrated in a 
prospective trial that diabetic subjects do not exhibit a 
significant circadian variation in the onset of AM[ and 
we have suggested that this is due to blunting of diurnal 
variation in physiological parameters, such as blood 
pressure and blood coagulability 75. 
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Unstable angina 
Unstable angina has been less extensively studied than 
AMI. In a prospective case-control study 76 we found 
that the three month mortality was 8.6% in diabetic 
patients and 2.5% in controls (p=O.I4). The one year 
mortality was 16.7% in diabetic patients and 5.4% in 
controls (p=O.29). Two other studies 77. 78 have shown 
that diabetes is a predictor of ad verse outcome after 
unstable angina; however both were part of a multiple 
subgroup analysis. In our study the frequency of AMI, 
coronary artery bypass grafting (CABG) and of further 
episodes of unstable angina were similar in the diabetic 
and control groups. Diabetic patients underwent 
coronary angiography and angioplasty less frequently 
than controls. This could be due to a higher frequency of 
ischaemia in diabetic subjects being silent. Indeed, of 
those who underwent coronary angiography, a higher 
proportion of diabetic patients needed CABG than 
controls . These data suggest that diabetic patients with 
unstable angina have more extensive coronary artery 
disease and that they should be more aggressively 
investigated. This might include Holter monitoring to 
detect silent ischaemia. 
Conclusions 
Diabetes mellitus is associated with an increased 
mortality ,md morbidity from coronary artery disease. 
One of the targets of the St. Vincent Declaration is to 
reduce death from coronary artery disease. This can be 
achieved by tighter glycaemic control and by modifying 
other risk factors for coronary artery disease. The latter 
includes stopping smoking, losing weight, treating 
hypertension and correcting dyslipidaemia by dietary 
manoeuvres and, if necessary, drug treatment. The 
landmark Diabetes Control and Complications trial 7<) 
has shown that tight glycaemic control decreases 
cardiovascular mortality in type I diabetic subjects. 
There is evidence that this also applies to type 2 diabetic 
subjects gO-H2. 
Although diabetic patients may have small vessel 
disease, they are also at an increased risk of having large 
vessel disease. Diabetic patients with suspected 
ischaemic heart disease should therefore be investigated 
along the same lines as their non-diabetic counterparts. 
This is often rewarded by finding disease that is 
amenable to angioplasty or bypass grafting. It should be 
borne 111 rnind, however, that the results of 
revascularisation procedures are worse in diabetic 
patients. 
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